Ligand residence time at G-protein-coupled receptors - Why we should take our time to study it

Molecular Pharmacology

Volumn 88, Issue 3, 2015, Pages 552-560

  Hoffmann, C ^a   Castro, M ^b   Rinken, A ^c   Leurs, R ^d   Hill, S J ^e   Vischer, H F ^d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^c UNIVERSITY OF TARTU   (Estonia)

^d AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; ACLIDINIUM BROMIDE; AMBRISENTAN; AZELASTINE; BOSENTAN; CETIRIZINE; DESLORATADINE; G PROTEIN COUPLED RECEPTOR; GLYCOPYRRONIUM BROMIDE; GSK 1004723; IPRATROPIUM BROMIDE; LEVOCETIRIZINE; MACITENTAN; MEPYRAMINE; TIOTROPIUM BROMIDE; FLUORESCENT DYE; LIGAND; PROTEIN BINDING;

ANISOTROPY; ARTICLE; BINDING ASSAY; CELL MEMBRANE; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG TARGETING; FLUORESCENCE ANISOTROPY; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; LIGAND BINDING; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; PRIORITY JOURNAL; PROTEIN CONFORMATION; QUARTZ CRYSTAL MICROBALANCE; RADIOASSAY; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; AGONISTS; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; KINETICS; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

AMINO ACID SEQUENCE; ANIMALS; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; HUMANS; KINETICS; LIGANDS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SURFACE PLASMON RESONANCE;

EID: 84939780109     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.099671     Document Type: Article

References (92)

1. Aastrup T (2013) Talking sense. Inno Pharm Tech 46:48-51.
2. Ambrosio M and Lohse MJ (2012) Nonequilibrium activation of a G-protein-coupled receptor. Mol Pharmacol 81:770-777.
3. Andaloussi M, Lim HD, van der Meer T, Sijm M, Poulie CB, de Esch IJ, Leurs R, and Smits RA (2013) A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. Bioorg Med Chem Lett 23:2663-2670.
4. Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West RE, Jr, Williams SM, Greenfeder S, Billah M, and Kreutner W et al. (2002) Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol 449:229-237.
5. Atlas D and Levitzki A (1977) Probing of beta-adrenergic receptors by novel fluorescent beta-adrenergic blockers. Proc Natl Acad Sci USA 74:5290-5294.
6. Aristotelous T, Hopkins AL, and Navratilova I (2015) Surface plasmon resonance analysis of seven-transmembrane receptors. Methods Enzymol 556:499-525.
7. Bocquet N, Kohler J, Hug MN, Kusznir EA, Rufer AC, Dawson RJ, Hennig M, Ruf A, Huber W, and Huber S (2015) Real-time monitoring of binding events on a thermostabilized human A2A receptor embedded in a lipid bilayer by surface plasmon resonance. Biochim Biophys Acta 1848:1224-1233.
8. Briddon SJ and Hill SJ (2007) Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand-receptor complexes. Trends Pharmacol Sci 28:637-645.
9. Calebiro D, Nikolaev VO, Gagliani MC, de Filippis T, Dees C, Tacchetti C, Persani L, and Lohse MJ (2009) Persistent cAMP-signals triggered by internalized G-proteincoupled receptors. PLoS Biol 7:e1000172.
10. Carroll MJ, Mauldin RV, Gromova AV, Singleton SF, Collins EJ, and Lee AL (2012) Evidence for dynamics in proteins as a mechanism for ligand dissociation. Nat Chem Biol 8:246-252.
11. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, and Pieper M (2009) Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 330:660-668.
12. Castro M, Nikolaev VO, Palm D, Lohse MJ, and Vilardaga JP (2005) Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci USA 102:16084-16089.
13. Christopher JA, Brown J, Doré AS, Errey JC, Koglin M, Marshall FH, Myszka DG, Rich RL, Tate CG, and Tehan B et al. (2013) Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem 56:3446-3455.
14. Christopoulos A (2014) Advances in G protein-coupled receptor allostery: from function to structure. Mol Pharmacol 86:463-478.
15. Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
16. Colquhoun D (2006) The quantitative analysis of drug-receptor interactions: a short history. Trends Pharmacol Sci 27:149-157.
17. Copeland RA (2011) Conformational adaptation in drug-target interactions and residence time. Future Med Chem 3:1491-1501.
18. Copeland RA, Pompliano DL, and Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739.
19. Cordeaux Y, Briddon SJ, Alexander SP, Kellam B, and Hill SJ (2008) Agonistoccupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells. FASEB J 22:850-860.
20. Corriden R, Kilpatrick LE, Kellam B, Briddon SJ, and Hill SJ (2014) Kinetic analysis of antagonist-occupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism. FASEB J 28:4211-4222.
21. Cupp ME, Nayak SK, Adem AS, and Thomsen WJ (2013) Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J Pharmacol Exp Ther 345:404-418.
22. Dahl G and Akerud T (2013) Pharmacokinetics and the drug-target residence time concept. Drug Discov Today 18:697-707.
23. De Amici M, Dallanoce C, Holzgrabe U, Tränkle C, and Mohr K (2010) Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev 30:463-549.
24. Dean T, Vilardaga JP, Potts JT, Jr, and Gardella TJ (2008) Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 22:156-166.
25. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, and Hammer R (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52: 537-544.
26. Fernández-Dueñas V, Gómez-Soler M, Jacobson KA, Kumar ST, Fuxe K, Borroto-Escuela DO, and Ciruela F (2012) Molecular determinants of A2AR-D2R allosterism: role of the intracellular loop 3 of the D2R. J Neurochem 123:373-384.
27. Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT, Gardella TJ, and Vilardaga JP (2009) Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol 5:734-742.
28. Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, and Nayler O (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662.
29. Gavaldà A, Miralpeix M, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, and Vilella D et al. (2009) Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 331:740-751.
30. Gavaldà A, Ramos I, Carcasona C, Calama E, Otal R, Montero JL, Sentellas S, Aparici M, Vilella D, and Alberti J et al. (2014) The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm Pharmacol Ther 28:114-121.
31. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, and Luttrell LM (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1ra1.
32. Gherbi K, Briddon SJ, and Hill SJ (2014) Detection of the secondary, low-affinity β1-adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP. Br J Pharmacol 171:5431-5445.
33. Gherbi K, May LT, Baker JG, Briddon SJ, and Hill SJ (2015) Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation. FASEB J 29:2859-2871.
34. Gillard M and Chatelain P (2006) Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol 530:205-214.
35. Gillard M, Van der Perren C, Massingham R, and Chatelain P (2002) Binding characteristics of [3H]levocetirizine to cloned human H1-histamine-receptors expressed in CHO cells. Inflam Res 51 (Suppl 1): S77-78.
36. Guo D, Hillger JM, IJzerman AP, and Heitman LH (2014) Drug-target residence time-a case for G protein-coupled receptors. Med Res Rev 34:856-892.
37. Guo D, Mulder-Krieger T, IJzerman AP, and Heitman LH (2012) Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 166:1846-1859.
38. Heym RG, Hornberger WB, Lakics V, and Terstappen GC (2015) Label-free detection of small-molecule binding to a GPCR in the membrane environment. Biochim Biophys Acta 1854:979-986.
39. Hill SJ, May LT, Kellam B, and Woolard J (2014) Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization. Br J Pharmacol 171:1102-1113.
40. Hoffmann C, Nuber S, Zabel U, Ziegler N, Winkler C, Hein P, Berlot CH, Bünemann M, and Lohse MJ (2012) Comparison of the activation kinetics of the M3 acetylcholine receptor and a constitutively active mutant receptor in living cells. Mol Pharmacol 82:236-245.
41. Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocana A, Bisello A, Hollis BW, Rosen CJ, Wysolmerski JJ, and Dann P et al. (2005) Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 20:1792-1803.
42. Huwiler KG, De Rosier T, Hanson B, and Vogel KW (2010) A fluorescence anisotropy assay for the muscarinic M1 G-protein-coupled receptor. Assay Drug Dev Technol 8:356-366.
43. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, Rasmussen SG, Sunahara RK, El-Samad H, and Huang B et al. (2013) Conformational biosensors reveal GPCR signalling from endosomes. Nature 495:534-538.
44. Junge F, Luh LM, Proverbio D, Schäfer B, Abele R, Beyermann M, Dötsch V, and Bernhard F (2010) Modulation of G-protein coupled receptor sample quality by modified cell-free expression protocols: a case study of the human endothelin A receptor. J Struct Biol 172:94-106.
45. Keserü GM and Swinney DC(2015) Thermodynamics and Kinetics of Drug Binding, Wiley, Heidelberg, Germany.
46. Kuhr FK, Smith KA, Song MY, Levitan I, and Yuan JX (2012) New mechanisms of pulmonary arterial hypertension: role of Ca2+ signaling. Am J Physiol Heart Circ Physiol 302:H1546-H1562.
47. Kuna RS, Girada SB, Asalla S, Vallentyne J, Maddika S, Patterson JT, Smiley DL, DiMarchi RD, and Mitra P (2013) Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic β-cells. Am J Physiol Endocrinol Metab 305:E161-E170.
48. Lohse MJ and Calebiro D (2013) Cell biology: Receptor signals come in waves. Nature 495:457-458.
49. Lohse MJ, Nuber S, and Hoffmann C (2012) Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacol Rev 64:299-336.
50. Louvel J, Guo D, Agliardi M, Mocking TA, Kars R, Pham TP, Xia L, de Vries H, Brussee J, and Heitman LH et al. (2014) Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. J Med Chem 57:3213-3222.
51. Lu H and Tonge PJ (2010) Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol 14:467-474.
52. Lu J and Willars GB (2013) Endothelin-converting enzyme-1 regulates the resensitisation of signalling by the glucagon-like peptide-1 receptor. Acta Pharmacol Sin 34 (Suppl S8):29.
53. May LT, Bridge LJ, Stoddart LA, Briddon SJ, and Hill SJ (2011) Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics. FASEB J 25:3465-3476.
54. Melamed E, Lahav M, and Atlas D (1976) Direct localisation of beta-adrenoceptor sites in rat cerebellum by a new fluorescent analogue of propranolol. Nature 261:420-422.
55. Middleton RJ, Briddon SJ, Cordeaux Y, Yates AS, Dale CL, George MW, Baker JG, Hill SJ, and Kellam B (2007) New fluorescent adenosine A1-receptor agonists that allow quantification of ligand-receptor interactions in microdomains of single living cells. J Med Chem 50:782-793.
56. Motulsky HJ and Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25:1-9.
57. Nikolaev VO, Hoffmann C, Bünemann M, Lohse MJ, and Vilardaga JP (2006) Molecular basis of partial agonism at the neurotransmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem 281:24506-24511.
58. Nosjean O, Souchaud S, Deniau C, Geneste O, Cauquil N, and Boutin JA (2006) A simple theoretical model for fluorescence polarization binding assay development. J Biomol Screen 11:949-958.
59. Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, Pan AC, Liu CW, Fung JJ, and Bokoch MP et al. (2013) The dynamic process of b(2)-adrenergic receptor activation. Cell 152:532-542.
60. Pan AC, Borhani DW, Dror RO, and Shaw DE (2013) Molecular determinants of drug-receptor binding kinetics. Drug Discov Today 18:667-673.
61. Paton WD and Rang HP (1965) The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptors. Proc R Soc Lond B Biol Sci 163:1-44.
62. Prenner L, Sieben A, Zeller K, Weiser D, and Häberlein H (2007) Reduction of highaffinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry 46:5106-5113.
63. Roed SN, Nøhr AC, Wismann P, Iversen H, Bräuner-Osborne H, Knudsen SM, and Waldhoer M (2015) Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking. J Biol Chem 290:1233-1243.
64. Roed SN, Wismann P, Underwood CR, Kulahin N, Iversen H, Cappelen KA, Schäffer L, Lehtonen J, Hecksher-Soerensen J, and Secher A et al. (2014) Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol 382:938-949.
65. Shonberg J, Kling RC, Gmeiner P, and Löber S (2015) GPCR crystal structures: Medicinal chemistry in the pocket. Bioorg Med Chem 23:3880-3906.
66. Shukla AK, Xiao K, and Lefkowitz RJ (2011) Emerging paradigms of b-arrestindependent seven transmembrane receptor signaling. Trends Biochem Sci 36:457-469.
67. Slack RJ, Hart AD, Luttmann MA, Clark KL, and Begg M (2011a) In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine. Eur J Pharmacol 670:586-592.
68. Slack RJ, Russell LJ, Hall DA, Luttmann MA, Ford AJ, Saunders KA, Hodgson ST, Connor HE, Browning C, and Clark KL (2011b) Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors. Br J Pharmacol 164:1627-1641.
69. Smits RA, Lim HD, van der Meer T, Kuhne S, Bessembinder K, Zuiderveld OP, Wijtmans M, de Esch IJ, and Leurs R (2012) Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics. Bioorg Med Chem Lett 22:461-467.
70. Sridharan R, Zuber J, Connelly SM, Mathew E, and Dumont ME (2014) Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. Biochim Biophys Acta 1838 (1 Pt A):15-33.
71. Stoddart LA, Vernall AJ, Denman JL, Briddon SJ, Kellam B, and Hill SJ (2012) Fragment screening at adenosine-A(3) receptors in living cells using a fluorescencebased binding assay. Chem Biol 19:1105-1115.
72. Stoddart LA, Johnston EKM, Wheal AJ, Goulding J, Robers MB, Machleidt T, Wood KV, Hill SJ, and Pfleger KDG (2015) Application of BRET to monitor ligandbinding to GPCRs. Nat Methods 12:661-663.
73. Sykes DA, Dowling MR, and Charlton SJ (2009) Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76:543-551.
74. Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, and Charlton SJ (2012) The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 343:520-528.
75. Sykes DA, Parry C, Reilly J, Wright P, Fairhurst RA, and Charlton SJ (2014) Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing "micro-pharmacokinetic/pharmacodynamic relationships" at the β2-adrenoceptor. Mol Pharmacol 85:608-617.
76. Tautermann CS, Kiechle T, Seeliger D, Diehl S, Wex E, Banholzer R, Gantner F, Pieper MP, and Casarosa P (2013) Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. J Med Chem 56:8746-8756.
77. Teague SJ (2003) Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2:527-541.
78. Tõntson L, Kopanchuk S, and Rinken A (2014) Characterization of 5-HT1A receptors and their complexes with G-proteins in budded baculovirus particles using fluorescence anisotropy of Bodipy-FL-NAN-190. Neurochem Int 67:32-38.
79. Tummino PJ and Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47:5481-5492.
80. van Unen J, Woolard J, Rinken A, Hoffmann C, Hill SJ, Goedhart J, Bruchas MR, Bouvier M, and Adjobo-Hermans M (2015) A perspective on studying GPCR signaling with RET biosensors in living organisms. Mol Pharmacol 88:589-595.
81. Vauquelin G and Charlton SJ (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161:488-508.
82. Vauquelin G and Charlton SJ (2013) Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol 168:1771-1785.
83. Veiksina S, Kopanchuk S, and Rinken A (2010) Fluorescence anisotropy assay for pharmacological characterization of ligand binding dynamics to melanocortin 4 receptors. Anal Biochem 402:32-39.
84. Veiksina S, Kopanchuk S, and Rinken A (2014) Budded baculoviruses as a tool for a homogeneous fluorescence anisotropy-based assay of ligand binding to G proteincoupled receptors: the case of melanocortin 4 receptors. Biochim Biophys Acta 1838 (1 Pt B):372-381.
85. Ventura AC, Bush A, Vasen G, Goldín MA, Burkinshaw B, Bhattacharjee N, Folch A, Brent R, Chernomoretz A, and Colman-Lerner A (2014) Utilization of extracellular information before ligand-receptor binding reaches equilibrium expands and shifts the input dynamic range. Proc Natl Acad Sci USA 111:E3860-E3869.
86. Vilardaga JP, Jean-Alphonse FG, and Gardella TJ (2014) Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol 10:700-706.
87. Wang W, Yin L, Gonzalez-Malerva L, Wang S, Yu X, Eaton S, Zhang S, Chen HY, LaBaer J, and Tao N (2014) In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance. Sci Rep 4:6609.
88. Weston C, Poyner D, Patel V, Dowell S, and Ladds G (2014) Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast. Br J Pharmacol 171:3651-3665.
89. Wieland K, Laak AM, Smit MJ, Kühne R, Timmerman H, and Leurs R (1999) Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J Biol Chem 274:29994-30000.
90. Woolf PJ and Linderman JJ (2003) Untangling ligand induced activation and desensitization of G-protein-coupled receptors. Biophys J 84:3-13.
91. Wright SC, Proverbio D, Valnohova J, Schulte G, and Aastrup T (2014) Label-free cell-based assay for the characterization of peptide receptor interactions. Int Pharm Industry 6:54-57.
92. Zhukov A, Andrews SP, Errey JC, Robertson N, Tehan B, Mason JS, Marshall FH, Weir M, and Congreve M (2011) Biophysical mapping of the adenosine A2A receptor. J Med Chem 54:4312-4323.